DOCSLIB.ORG

Pilot Study Couple Recruitment, Triage and Reporting Plan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

--------------------------------------------------------------------------, Metropolitan Area Couples can learn about the study through pamphlets and posters in the Pilot Study Couple Recruitment, Triage and Reporting Plan ............ Information Pack provided by clinical GSWA clinic or by approaching clinical geneticist or genetic counsellor geneticist or genetic counsellor during meeting Couples will bring home the Couples who are Couples will book an appointment Information Pack to read through not interested can i----.i· participate in the the Participants Information Sheet . Couples who decide to with either a genetic counsellor or study by clinical geneticist and consider their decisions to completing a withdraw from the study can participate . decliner'ssurvey . decide if they want their sample and data destroyed A clinical geneticist or genetic Genetic counsellor will collect signed and removed from the study counsellor will provide pre-test ' . counselling and answer any questions ...........·. Participant Consent Forms and send them to researchers, keeping a copy DECIDE TO WITHDRAW couples may have about the study. of the form for their records Couples will sign the PICFs I I Couples will bring Through PathWest courier NOT INTERESTED Couples will receive a PathWest PathWest Study Blood collected at services, blood samples sent to ....,_ ______ .......: No further actions or participate Study Collection Form from genetic Collection Form to any PathWest collection PathWest Genomics Diagnostic counsellor in the decliner's survey PathWest collection centres Laboratory for DNA L-------------------------------------------------------------------------- centres sequencing ---------------- Rural Area Information Pack in Busselton • Testing Centre Next generation Library preparation, will contain a list DNA extraction Sample processing and unique Couples can learn about the of participating Variant filtering and sequencing data feed capture and next GP clinics and - and - identifying numbers given to study through pamphlets and Information Pack readily contact details prioritisation through Agilent generation posters in GP clinics, available at the Busselton ------- ------- ™ sequencing each couple . ----- ·r1 Alissa sequencing advertisements in local Testing Centre or participating newspaper, or Townhall GP clinics Information Pack in GP clinics will ' . DO NOT WANT meeting contain a space RESULTSBACK for participating Study GC informs couples of ' . Dr's stamp Are cou pies at-risk? Report generated and results and refers to GSWA Couples will bring home the Defined as both AT HIGH - . for follow up appointment. Couples will book an Information Pack to read - l sent back to the study Manual curation of couple having a Class4 RISK Copy of report and appointment with a through Participants genetic counsellor appointment referral to participating GP Information Sheet and consider l variants present in both or ClassS variant in the referring health professional their decisions to participate Couples who are not interested couples same gene or in the X­ ' can participate linked gene for female AT LOW ' . in the study by Couples shown to be at Practice manager will collect RISK At-risk couples counselled Participating GP will provide completing a partner low risk of having a child signed Participant Consent by GSWA genetic counsellor pre-test counselling and decliner's survey with one of the conditions Forms and send them to about limitations, condition answer any questions couples being screened for will researchers, keeping a copy of specific information, may have about the study Report sent to receive a letter explaining the form for their records this information, and will reproductive options and I study genetic impact on relatives NOT INTERESTED counsellor not receive information ' • about individual carrier No further actions or Participating GP will issue status. Copy of report and Couples decide what participate in the decliner's PathWest Study Collection I I letter sent to referring . reproductive methods they survey Form to couoles I I health professional --------------------------------------------------------------------------J decide to ursue Preconception carrier screening panel gene list Gene Disease name Pheme # Chr# Disease Type AARS2 Combined oxidative phosphorylation deficiency 8 614096 6p21.1 Mitochondrial ABAT GABA-transaminase deficiency 613163 16p13.2 Neurodegenerative ABCA12 Ichthyosis autosomal recessive 4B (harlequin) 242500 2q35 Cutaneous ABCA3 Surfactant metabolism dysfunction pulmonary 3 610921 16p13.3 Respiratory ABCC6 Arterial calcification generalized of infancy 2 614473 16p13.11 Cardiovascular ABCD1 Adrenoleukodystrophy 300100 Xq28 Neurodegenerative ACAD9 Mitochondrial complex I deficiency due to ACAD9 deficiency 611126 3q21.3 Mitochondrial ACADS Short Chain Acyl-CoA Dehydrogenase Deficiency 201470 12q24.31 Metabolic ACADVL VLCAD deficiency 201475 17p13.1 Metabolic ACAT1 Ketothiolase Deficiency/Beta-ketothiolase deficiency 203750 11q22.3 Metabolic ACE Renal tubular dysgenesis 267430 17q23.3 Renal ADAMTS2 Ehlers-Danlos syndrome type VIIC 225410 5q35.3 Cutaneous ADAMTSL2 Geleophysic dysplasia 1 231050 9q34.2 Lysosomal AGA aspartylglucosaminuria 208400 4q34.3 Lysosomal AGK Sengers syndrome 212350 7q34 Mitochondrial AGL Glycogen storage disease IIIa 232400 1p21.2 Metabolic AGT Renal tubular dysgenesis 267430 1q42.2 Renal AGTR1 Renal tubular dysgenesis 267430 3q24 Renal AGXT Primary Hyperoxaluria Type 1 259900 2q37.3 Metabolic AIRE Polyglandular Autoimmune Syndrome Type 1 240300 21q22.3 Immunodeficiency AK2 Reticular dysgenesis 267500 1p35.1 Immunodeficiency ALDH3A2 Sjogren-Larsson Syndrome 270200 17p11.2 Developmental ALDH7A1 Epilepsy pyridoxine-dependent 266100 5q23.2 Neurologic ALG1 Congenital disorder of glycosylation type Ik 608540 16p13.3 Metabolic ALG8 Congenital disorder of glycosylation type Ih 608104 11q14.1 Metabolic ALPL Hypophosphatasia infantile 241500 1p36.12 Skeletal AMT Glycine encephalopathy 605899 3p21.31 Metabolic ANTXR2 Hyaline fibromatosis syndrome 228600 4q21.21 Cutaneous APOPT1 Mitochondrial complex IV deficiency 220110 14q32.33 Mitochondrial ARHGDIA Nephrotic syndrome type 8 615244 17q25.3 Renal ARSA Metachromatic leukodystrophy 250100 22q13.33 Lysosomal ARSB Mucopolysaccharoidosis Type VI/Maroteaux-Lamy (AJ Population) 253200 5q14.1 Lysosomal ARX Hydranencephaly with abnormal genitalia 300215 Xp21.3 Developmental ASAH1 Farber lipogranulomatosis 228000 8p22 Lysosomal ASL Argininosuccinic aciduria 207900 7q11.21 Metabolic ASNS Asparagine synthetase deficiency 615574 7q21.3 Metabolic ASPA Canavan disease 271900 17p13.2 Metabolic ASS1 Citrullinemia 215700 9q34.11 Metabolic Gene list (continue) ATM Ataxia-Telangiectasia 208900 11q22.3 Neurodegenerative ATP7A Menkes disease 309400 Xq21.1 Metabolic ATP7B Wilson Disease 277900 13q14.3 Metabolic ATPAF2 Mitochondrial complex V ATP synthase) deficiency nuclear type 1 604273 17p11.2 Mitochondrial B4GAT1 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies) type A 615287 11q13.2 Neuromuscular B9D2 Meckel syndrome 10 614175 19q13.2 Developmental BBS1 Bardet-Biedl Syndrome BBS1-Related 209900 11q13.2 Developmental BBS10 Bardet-Biedl Syndrome BBS10-Related 615987 12q21.2 Developmental BCAP31 Deafness dystonia and cerebral hypomyelination 300475 Xq28 Neurologic BCKDHA Maple syrup urine disease type Ia 248600 19q13.2 Metabolic BCKDHB Maple syrup urine disease type Ib 248600 6q14.1 Metabolic BCOR Microphthalmia syndromic 2 300166 Xp11.4 Developmental BCS1L GRACILE syndrome 603358 2q35 Metabolic BLM Bloom Syndrome (AJ Population) 210900 15q26.1 Developmental BMPER Diaphanospondylodysostosis 608022 7p14.3 Skeletal BOLA3 Multiple mitochondrial dysfunctions syndrome 2 614299 2p13.1 Mitochondrial BRAT1 Rigidity and multifocal seizure syndrome lethal neonatal 614498 7p22.3 Neurodegenerative BSCL2 Encephalopathy progressive with or without lipodystrophy 615924 11q12.3 Neurodegenerative BTD Biotinidase Deficiency 253260 3p25.1 Metabolic C10orf2 Mitochondrial DNA depletion syndrome 7 (hepatocerebral type) 271245 10q24.31 Mitochondrial CBS Homocystinuria ( B6-responsive and nonresponsive types) 236200 21q22.3 Metabolic CC2D2A Meckel syndrome 6 612284 4p15.32 Developmental CD27 Lymphoproliferative syndrome 2 615122 12p13.31 Immunodeficiency CD3D Immunodeficiency 19 615617 11q23.3 Immunodeficiency CD3E Immunodeficiency 18 615615 11q23.3 Immunodeficiency CD40LG Immunodeficiency X-linked with hyper-IgM 308230 Xq26.3 Immunodeficiency CEP120 Short-rib thoracic dysplasia 13 with or without polydactyly 616300 5q23.2 Skeletal CEP290 Meckel syndrome 4 611134 12q21.32 Developmental CFL2 Nemaline myopathy 7 autosomal recessive 610687 14q13.1 Neuromuscular CFTR Cystic Fibrosis 277180 7q31.2 Developmental CHRNA1 Multiple pterygium syndrome lethal type 253290 2q31.1 Neuromuscular CHRND Multiple pterygium syndrome lethal type 253290 2q37.1 Neuromuscular CHRNG Escobar syndrome 265000 2q37.1 Developmental CHUK Cocoon syndrome 613630 10q24.31 Developmental CIITA Bare lymphocyte syndrome type II complementation group A 209920 16p13.13 Immunodeficiency CLN3 CLN3-Related Neuronal Ceroid Lipofuscinosis/Juvenile Batten Disease 204200 16p11.2 Neurodegenerative CLN5 Ceroid lipofuscinosis neuronal 5 256731 13q22.3 Neurodegenerative CLN6 Ceroid lipofuscinosis neuronal 6 204300 15q23 Neurodegenerative Gene list (continue) CLN8 Ceroid lipofuscinosis neuronal 8 600143 8p23.3 Neurodegenerative CLPB 3-methylglutaconic aciduria type VII with cataracts neurologic
Recommended publications
  • New ZMPSTE24 (FACE1) Mutations in Patients Affected with Restrictive

    New ZMPSTE24 (FACE1) Mutations in Patients Affected with Restrictive

    New ZMPSTE24 (FACE1) mutations in patients affected with restrictive dermopathy or related progeroid syndromes and mutation update Claire Navarro, Patrice Roll, Vera Esteves-Vieira, Sebastien Courrier, Amandine Boyer, Thuy Duong Nguyen, Le Thi Thanh Huong, Peter Meinke, Winnie Schröder, Valérie Cormier-Daire, et al. To cite this version: Claire Navarro, Patrice Roll, Vera Esteves-Vieira, Sebastien Courrier, Amandine Boyer, et al.. New ZMPSTE24 (FACE1) mutations in patients affected with restrictive dermopathy or related progeroid syndromes and mutation update. European Journal of Human Genetics, Nature Publishing Group, 2013, 22 (8), pp.1002-1011. 10.1038/ejhg.2013.258. hal-01664301 HAL Id: hal-01664301 https://hal-amu.archives-ouvertes.fr/hal-01664301 Submitted on 20 Dec 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. New ZMPSTE24 (FACE1) mutations in patients affected with restrictive dermopathy or related progeroid syndromes and mutation update Claire Laure Navarro*,1,2, Vera Esteves-Vieira3,Se´bastien Courrier1,2, Amandine Boyer3, Thuy Duong
  • Identification of Novel Pathways That Promote Anoikis Through Genome-Wide Screens

    Identification of Novel Pathways That Promote Anoikis Through Genome-Wide Screens

    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2016-10-14 Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens Victoria E. Pedanou University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Biology Commons, and the Cancer Biology Commons Repository Citation Pedanou VE. (2016). Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens. GSBS Dissertations and Theses. https://doi.org/10.13028/M27G6D. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/889 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. i TITLE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY OCTOBER 14TH, 2016 CANCER BIOLOGY ii SIGNATURE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU This work was undertaken in the Graduate School of Biomedical Sciences Cancer Biology The signature of the Thesis Advisor signifies validation of Dissertation content ___________________________ Michael R. Green, Thesis Advisor The signatures of the Dissertation Defense Committee signify completion and approval as to style and content of the Dissertation __________________________________ Eric H.
  • Leigh Syndrome: One Disorder, More Than 75 Monogenic Causes

    Leigh Syndrome: One Disorder, More Than 75 Monogenic Causes

    Title: Leigh Syndrome: One disorder, more than 75 monogenic causes Running head: Leigh Syndrome: One disorder, many genes Author list: Nicole J. Lake, MSc,1,2 Alison G. Compton, PhD,1,2 Shamima Rahman, MD, PhD,3 and David R. Thorburn, PhD1,2,4 Affiliations: From the 1Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia; 2Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia; 3Mitochondrial Research Group, Genetics and Genomic Medicine, Institute of Child Health, University College London and Metabolic Unit, Great Ormond Street Hospital, London, United Kingdom; 4Victorian Clinical Genetic Services, Royal Children's Hospital, Melbourne, Victoria, Australia. Corresponding author: Prof. David Thorburn Email [email protected] Telephone +61 3 8341 6235 Fax +61 3 8341 6212 Address Murdoch Childrens Research Institute, The Royal Children’s Hospital, 50 Flemington Rd, Parkville, Victoria, 3052, Australia Number of characters in the title and running head: 51 and 35, respectively Number of words in the abstract (107), and the body of manuscript not including abstract (4877) Number of figures (3), colour figures (1/3), and tables (3) 1 Abstract Leigh syndrome is the most common pediatric presentation of mitochondrial disease. This neurodegenerative disorder is genetically heterogeneous, and to date pathogenic mutations in more than 75 genes have been identified, encoded by two genomes (mitochondrial and nuclear). More than a third of these disease genes have been characterized in the last 5 years alone, reflecting the significant advances made in understanding its etiological basis. We review the diverse biochemical and genetic etiology of Leigh syndrome and associated clinical, neuroradiological and metabolic features that can provide clues for diagnosis.
  • Exophilin-5 Regulates Allergic Airway Inflammation by Controlling IL-33–Mediated Th2 Responses

    Exophilin-5 Regulates Allergic Airway Inflammation by Controlling IL-33–Mediated Th2 Responses

    The Journal of Clinical Investigation RESEARCH ARTICLE Exophilin-5 regulates allergic airway inflammation by controlling IL-33–mediated Th2 responses Katsuhide Okunishi,1 Hao Wang,1 Maho Suzukawa,2,3 Ray Ishizaki,1 Eri Kobayashi,1 Miho Kihara,4 Takaya Abe,4,5 Jun-ichi Miyazaki,6 Masafumi Horie,7 Akira Saito,7 Hirohisa Saito,8 Susumu Nakae,9 and Tetsuro Izumi1 1Laboratory of Molecular Endocrinology and Metabolism, Department of Molecular Medicine, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan. 2National Hospital Organization Tokyo National Hospital, Tokyo, Japan. 3Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan. 4Laboratory for Animal Resource Development and 5Genetic Engineering, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan. 6Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan. 7Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 8Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan. 9Laboratory of Systems Biology, Center for Experimental Medicine and Systems Biology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. A common variant in the RAB27A gene in adults was recently found to be associated with the fractional exhaled nitric oxide level, a marker of eosinophilic airway inflammation. The small GTPase Rab27 is known to regulate intracellular vesicle traffic, although its role in allergic responses is unclear. We demonstrated that exophilin-5, a Rab27-binding protein, was predominantly expressed in both of the major IL-33 producers, lung epithelial cells, and the specialized IL-5 and IL-13 producers in the CD44hiCD62LloCXCR3lo pathogenic Th2 cell population in mice.
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • Orphanet Report Series Rare Diseases Collection

    Orphanet Report Series Rare Diseases Collection

    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
  • Mackenzie's Mission Gene & Condition List

    Mackenzie's Mission Gene & Condition List

    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
  • Psykisk Utviklingshemming Og Forsinket Utvikling

    Psykisk Utviklingshemming Og Forsinket Utvikling

    Psykisk utviklingshemming og forsinket utvikling Genpanel, versjon v03 Tabellen er sortert på gennavn (HGNC gensymbol) Navn på gen er iht. HGNC >x10 Andel av genet som har blitt lest med tilfredstillende kvalitet flere enn 10 ganger under sekvensering x10 er forventet dekning; faktisk dekning vil variere. Gen Gen (HGNC Transkript >10x Fenotype (symbol) ID) AAAS 13666 NM_015665.5 100% Achalasia-addisonianism-alacrimia syndrome OMIM AARS 20 NM_001605.2 100% Charcot-Marie-Tooth disease, axonal, type 2N OMIM Epileptic encephalopathy, early infantile, 29 OMIM AASS 17366 NM_005763.3 100% Hyperlysinemia OMIM Saccharopinuria OMIM ABCB11 42 NM_003742.2 100% Cholestasis, benign recurrent intrahepatic, 2 OMIM Cholestasis, progressive familial intrahepatic 2 OMIM ABCB7 48 NM_004299.5 100% Anemia, sideroblastic, with ataxia OMIM ABCC6 57 NM_001171.5 93% Arterial calcification, generalized, of infancy, 2 OMIM Pseudoxanthoma elasticum OMIM Pseudoxanthoma elasticum, forme fruste OMIM ABCC9 60 NM_005691.3 100% Hypertrichotic osteochondrodysplasia OMIM ABCD1 61 NM_000033.3 77% Adrenoleukodystrophy OMIM Adrenomyeloneuropathy, adult OMIM ABCD4 68 NM_005050.3 100% Methylmalonic aciduria and homocystinuria, cblJ type OMIM ABHD5 21396 NM_016006.4 100% Chanarin-Dorfman syndrome OMIM ACAD9 21497 NM_014049.4 99% Mitochondrial complex I deficiency due to ACAD9 deficiency OMIM ACADM 89 NM_000016.5 100% Acyl-CoA dehydrogenase, medium chain, deficiency of OMIM ACADS 90 NM_000017.3 100% Acyl-CoA dehydrogenase, short-chain, deficiency of OMIM ACADVL 92 NM_000018.3 100% VLCAD
  • Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021

    Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021

    Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021 INDIVIDUAL MARKETPLACE | PROMEDICA MEDICARE PLAN | PPO GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual policyholder terms, conditions, exclusions and limitations contract. It does not constitute a contract or guarantee regarding coverage or reimbursement/payment. Paramount applies coding edits to all medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. This medical policy is solely for guiding medical necessity and explaining correct procedure reporting used to assist in making coverage decisions and administering benefits. SCOPE X Professional X Facility DESCRIPTION A genetic test is the analysis of human DNA, RNA, chromosomes, proteins, or certain metabolites in order to detect alterations related to a heritable or acquired disorder. This can be accomplished by directly examining the DNA or RNA that makes up a gene (direct testing), looking at markers co-inherited with a disease-causing gene (linkage testing), assaying certain metabolites (biochemical testing), or examining the chromosomes (cytogenetic testing). Clinical genetic tests are those in which specimens are examined and results reported to the provider or patient for the purpose of diagnosis, prevention or treatment in the care of individual patients. Genetic testing is performed for a variety of intended uses: Diagnostic testing (to diagnose disease) Predictive
  • Rab27a and Rab27b Control Different Steps of the Exosome Secretion Pathway

    Rab27a and Rab27b Control Different Steps of the Exosome Secretion Pathway

    ARTICLES Rab27a and Rab27b control different steps of the exosome secretion pathway Matias Ostrowski1,2, Nuno B. Carmo3,12, Sophie Krumeich1,2,12, Isabelle Fanget10,12, Graça Raposo4,2, Ariel Savina1,2, Catarina F. Moita3, Kristine Schauer4,2, Alistair N. Hume5, Rui P. Freitas3, Bruno Goud4,2, Philippe Benaroch1,2, Nir Hacohen8,9, Mitsunori Fukuda11, Claire Desnos10, Miguel C. Seabra5,6,7, François Darchen10, Sebastian Amigorena1,2, Luis F. Moita3,13 and Clotilde Thery1,2,13 Exosomes are secreted membrane vesicles that share structural and biochemical characteristics with intraluminal vesicles of multivesicular endosomes (MVEs). Exosomes could be involved in intercellular communication and in the pathogenesis of infectious and degenerative diseases. The molecular mechanisms of exosome biogenesis and secretion are, however, poorly understood. Using an RNA interference (RNAi) screen, we identified five Rab GTPases that promote exosome secretion in HeLa cells. Among these, Rab27a and Rab27b were found to function in MVE docking at the plasma membrane. The size of MVEs was strongly increased by Rab27a silencing, whereas MVEs were redistributed towards the perinuclear region upon Rab27b silencing. Thus, the two Rab27 isoforms have different roles in the exosomal pathway. In addition, silencing two known Rab27 effectors, Slp4 (also known as SYTL4, synaptotagmin-like 4) and Slac2b (also known as EXPH5, exophilin 5), inhibited exosome secretion and phenocopied silencing of Rab27a and Rab27b, respectively. Our results therefore strengthen the link between MVEs and exosomes, and introduce ways of manipulating exosome secretion in vivo. Exosomes are membrane vesicles secreted into the extracellular space membrane of MVEs into the lumen of these endosomes14.
  • LMNA-Related Disorders

    LMNA-Related Disorders

    LMNA-Related Disorders Indications for Ordering Genetics To confirm a clinical diagnosis of a LMNA-related disorder, Genes: LMNA such as: • Hutchinson-Gilford progeria syndrome (HGPS) Inheritance: See table • Emery-Dreifuss muscular dystrophy type 2 (EDMD2) Penetrance: Varies by syndrome • Limb-Girdle muscular dystrophy 1B (LGMD1B) • Charcot-Marie-Tooth 2B1 (CMT2B1) Structure/Function • Familial partial lipodystrophy, Dunnigan type (FPLD) • Composed of 12 exons • LMNA-related dilated cardiomyopathy (DCM) • LMNA encodes isoforms A and C of the lamin protein • Mandibulo-acral dysplasia (MAD) o Structural component of the nuclear membrane • Atypical Werner syndrome (WS) o Anchors heterochromatin to the inner nuclear • Restrictive dermopathy (RD) membrane • Other, intermediate phenotypes Variants Test Description • Alternative splicing of the LMNA gene produces two proteins (lamin A and C) Polymerase chain reaction (PCR) followed by bidirectional • Variants occur throughout the gene sequencing of all coding regions and intron/exon o Predominantly missense boundaries of the LMNA gene o p.G608G variant in exon 11 . Present in all individuals with HGPS Tests to Consider Test Interpretation Primary Tests LMNA-Related Disorders (LMNA) Sequencing 2004543 Sensitivity/Specificity • Confirm suspected laminopathy caused by LMNA variants, • Clinical sensitivity: dependent on the specific LMNA- including HGPS, EDMD2, LGMD1B, CMT2B1, FPLD , DCM, related disorder MAD, WS, or RD • Analytic sensitivity/specificity: 99% Related Test Results Familial Mutation,
  • From Gene Expression to the Clinic

    From Gene Expression to the Clinic

    UvA-DARE (Digital Academic Repository) Biomarker discovery for asthma phenotyping: From gene expression to the clinic Wagener, A.H. Publication date 2016 Document Version Final published version Link to publication Citation for published version (APA): Wagener, A. H. (2016). Biomarker discovery for asthma phenotyping: From gene expression to the clinic. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:02 Oct 2021 CHAPTER 4 Supporting Information File dsRNA-induced changes in gene expression pro les of primary nasal and bronchial epithelial cells from patients with asthma, rhinitis and controls methods Primary epithelial cell culture Epithelal cell cultures were done as previously described (1). Primary cells were obtained by first digesting the biopsies and brushes with collagenase 4 (Worthington Biochemi- cal Corp., Lakewood, NJ, USA) for 1 hour in Hanks’ balanced salt solution (Sigma-Aldrich, Zwijndrecht, The Netherlands).